Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target

Xiao-Lu Ma¹†, Yun-Fan Sun²†, Bei-Li Wang¹, Min-Na Shen¹, Yan Zhou¹, Jian-Wen Chen², Bo Hu², Zi-Jun Gong², Xin Zhang², Ya Cao³, Bai-shen Pan¹, Jian Zhou², Jia Fan², Wei Guo¹* and Xin-Rong Yang²*

Abstract

Backgrounds: The role of sphere-forming culture in enriching subpopulations with stem-cell properties in hepatocellular carcinoma (HCC) is unclear. The present study investigates its value in enriching cancer stem cells (CSCs) subpopulations and the mechanism by which HCC CSCs are maintained.

Methods: HCC cell lines and fresh primary tumor cells were cultured in serum-free and ultra-low attachment conditions to allow formation of HCC spheres. In vitro and in vivo experiments were performed to evaluate CSC characteristics. Expression levels of CSC-related genes were assessed by qRT-PCR and the correlation between sphere formation and clinical characteristics was investigated. Finally, gene expression profiling was performed to explore the molecular mechanism underlying HCC CSC maintenance.

Results: We found that both cell lines and primary tumor cells formed spheres. HCC spheres possessed the capacity for self-renewal, proliferation, drug resistance, and contained different subpopulations of CSCs. Of interest, 500 sphere-forming Huh7 cells or 200 primary tumor cells could generate tumors in immunodeficient animals. Sphere formation correlated with size, multiple tumors, satellite lesions, and advanced stage. Further investigation identified that the PPARα-SCD1 axis plays an important role in maintenance of the CSC properties of HCC sphere cells by promoting nuclear accumulation of β-Catenin. Inhibition of SCD1 interfered with sphere formation, down-regulated expression of CSC-related markers, and reduced β-Catenin nuclear accumulation.

Conclusions: Sphere-forming culture can effectively enrich subpopulations with stem-cell properties, which are maintained through activation of the PPARα-SCD1 axis. Therefore, we suggest that targeting the SCD1-related CSC machinery might provide a novel insight into HCC treatment.

Keywords: Cancer stem cell, Hepatocellular carcinoma, Stearoyl-CoA desaturase 1, Sphere-forming assay

Background

Hepatocellular carcinoma (HCC) is the fifth most prevalent malignancies in the world and third most frequent cause of cancer death [1]. Currently, surgery remains the most effective treatment with curative potential; however, only about 10–20% of patients with HCC are eligible for surgical intervention [2–4]. Meanwhile, more than 50% patients will have tumor relapse and metastasis during the five years following curative resection [4]. Thus, a better understand of
HCC biology and behavior will lead to advances in treatment.

The cancer stem cell (CSC) hypothesis posits that a small subset of cancer cells, with stem cell-like properties, has the capacity to induce tumor recurrence or metastasis, driving tumor progression and resistance to traditional therapies [5–7]. Targeted therapies aimed at eradicating CSCs might lead to the development of more effective treatment strategies [8]. In HCC, CSCs were first defined as a side population [9]. However, isolation of the side population using Hoechst dye staining may not accurately identify the real CSC population, due to an artifact of Hoechst 33342 toxicity rather than their intrinsic stem-cell properties.

Recently, HCC CSCs were identified based on the expression of various cell surface markers, including CD90 [10], CD13 [11], CD133 [12], epithelial cell adhesion molecular (EpCAM) [13], CD24 [14], OV6 [15], and Intercellular adhesion molecule 1 (ICAM1) [16]. However, these markers are not expressed exclusively in liver CSCs and their distribution in HCC is heterogeneous. Given the lack of HCC CSC-specific biomarkers, we aimed to develop alternative methods for isolating HCC CSCs.

The sphere-forming assay was first introduced as a functional approach for studying adult stem cells [17] and has been widely used to evaluate the stem properties of proposed CSC populations [18–23]. Using anchorage-independent sphere culture with serum-free, non-adherent, and nutritionally deficient conditions, differentiated tumor cells undergo apoptosis, while CSCs survive, adapt, and proliferate [17, 24]. This experimental approach is based on inherent characteristics of CSCs, it can enrich relatively whole subpopulations of CSCs regardless of their expression patterns. Sphere culture approach thus represents an optimal method for enriching CSC subpopulations from whole tumors. Recently, sphere formation has been used to enrich the potential CSC subpopulation in HCC cell lines [25, 26]. However, there are currently no published data that comprehensively demonstrate the CSC properties of HCC sphere cells, particularly those derived from primary patient tissues.

In this study, we enriched the CSC subpopulation from HCC tumor tissues and cell lines using sphere culture, and evaluated the differential expression profiles of tumor sphere and parental cells to explore the potential mechanism of CSC maintenance. We found that sphere-forming culture effectively enriched the HCC CSC subpopulation and promotes CSC properties via activation of the peroxisome proliferator-activated receptor-alpha (PPARα)-stearoyl-CoA desaturase (SCD1) axis. We suggest that targeting the SCD1 signaling pathway might be a novel therapeutic approach for the treatment of HCC.

Methods and materials
Cell lines and cell culture
Huh7 and Hep3B cell lines were provided by the Cell Bank at the Institute of Biochemistry and Cell Biology, China Academy of Science (Shanghai, China). Both cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), supplemented with 100 IU/ml penicillin and 100 μg/ml streptomycin, and incubated at 37 °C in a humidified atmosphere with 5% CO2. All cell culture reagents were obtained from Gibco (Invitrogen, USA).

Sphere-forming assay
Serum-free medium for sphere culture was composed of DMEM/F12 medium supplemented with 100 IU/ml penicillin, 100 μg/ml streptomycin, 20 ng/ml human recombinant epidermal growth factor, 20 ng/ml human recombinant basic fibroblast growth factor, 1% non-essential amino acids, 1% GlutaMax, 2% B27 supplement (Invitrogen, USA), and 1% methylcellulose (Sigma, USA). HCC cells were cultured at a density of 1000 cells/ml; when spheres reached a diameter of 100 μm, the sphere-forming efficiency was calculated and spheres were collected for further use [13].

Immunofluorescent staining
Spheres were fixed in 4% paraformaldehyde and blocked with 5% bovine serum albumin. Antibodies, including phycoerythrin (PE)-conjugated mouse anti-human CD133 and PE-conjugated mouse anti-human EpCAM (both 1:50, MiltenyBiotec, Germany) were added and incubated overnight at 4 °C. After washing with phosphate-buffered saline three times, spheres were counterstained with DAPI (Sigma-Aldrich, USA). For β-Catenin staining, 0.1% Triton was used for permeabilization. After blocking, mouse anti-human β-Catenin antibodies (BioLegend, 1:30) were added and incubated overnight at 4 °C. Sphere cells were also counterstained with DAPI (Sigma-Aldrich, USA). Images were captured using an IX-71 fluorescent microscope (Olympus, Japan).

Colony formation assay
Once they reached a diameter of 100 μm, HCC spheres were collected through gentle centrifugation, dissociated with trypsin–EDTA (Invitrogen, USA), and mechanically disrupted with a pipette. The resulting cells were gently centrifuged to remove trypsin. Single cells were seeded in DMEM with 10% FBS (Gibco, USA) at a density of 2000 cells per well in a 6-well plate (Corning, USA). Parental Huh7 cells were seeded at the same density as a control population to evaluate colony-forming capacity. After two weeks, the colony-forming ability was assessed by counting the number of colonies (> 70 cells) under a microscope after staining with crystal violet (Sigma-
\[ \text{μm} \text{ with 25 ng inhibition, Huh7 and Hep3B cells were treated before resection. Surgical specimens were collected from patients at Zhongshan Hospital in September 2013. Twenty-five fresh HCC tissue samples were collected.\]}

In vitro differentiation assay
Hep3B and Huh7 cells were grown in serum-free conditions to induce initial sphere formation, then 10% FBS was added to induce HCC sphere differentiation. FBS was removed and the first differentiated sphere cells were grown in serum-free conditions again to induce the second sphere formation. 10% FBS was added to induce differentiation of the second HCC spheres. This process was performed once more to generate three rounds of spheres and differentiated cells. The three sets of HCC spheres and differentiated sphere cells were harvested and RNA was extracted for PCR analysis.

RNA extraction and quantitative RT-PCR (qRT-PCR)
Total cellular RNA extraction was performed using a RNeasy mini kit (Qiagen, Germany) and cDNA was synthesized using the Quantitect Reverse Transcription Kit (Qiagen, Germany) according to the manufacturer's instructions. Target genes were quantified using FastStart Universal SYBR Green Master (Roche diagnostics, Germany) and DNA amplification was carried out using a LightCycler 480 (Roche Diagnostics, Germany). The relative quantities of target gene mRNAs compared to an internal control were determined using the \( \Delta \text{Cq} \) method. PCR conditions were as follows: 5 min at 95 °C, followed by 40 cycles of 95°C for 10 s and 60°C for 60 s. GAPDH was used as an internal control. Primers and probes are listed in Additional file 1: Table S1.

Drug treatment
The sensitivity of normal HCC cells and sphere HCC cells to chemotherapeutic drugs was measured using a Cell Counting Kit-8 (CCK-8) assay (Dojinno, Japan). Cells were seeded at a density of 1 \( \times \) 10^3 of cells in 96-well plates, and were incubated with 80 mM 5-Fluorouracil (5-FU, Sigma, USA), 5 \( \mu \text{mol/L} \) Sorafenib (MCE, USA), or 2 \( \mu \text{mol/L} \) Doxorubicin (MCE, USA) for 48, 72, and 96 h. All experiments were performed in triplicate. CCK-8 reagent was then added to each well according to the manufacturer’s instructions. For PPAR\( \alpha \) signaling inhibition, Huh7 and Hep3B cells were treated with 25 \( \mu \text{M} \) GW6471 (Sigma, USA), a PPAR\( \alpha \) inhibitor, for 48 h. For SCD1 inhibition, Huh7 and Hep3B cells were treated with 20 \( \mu \text{M} \) PluriSln #1 for 48 h.

Fresh clinical tissue specimens
Twenty-five fresh HCC tissue samples were collected from patients at Zhongshan Hospital in September 2013. These patients received no previous local or systemic treatment before resection. Surgical specimens were obtained at the time of resection from all patients. All samples were received in the laboratory within one hour, immediately mechanically disaggregated and digested with type IV collagenase (Gibco, USA), and re-suspended in DMEM medium. Single-cell suspensions were obtained by filtration through a 40 \( \mu \text{m} \) filter. Red blood cells were lysed with ACK buffer (Invitrogen, USA). The number of viable cells was counted and analyzed using Trypan blue. Isolated primary cells were then cultured in serum-free medium at a density of 20,000/well in an ultra-low attachment 6-well plate [11]. Approval for the use of human subjects was obtained from the research ethics committee of Zhongshan Hospital. Written informed consent was obtained from each subject enrolled in this study.

Tumorigenicity experiments
In our study, tumorigenicity was defined as the capacity of a certain cell number, following serial dilution, to form tumor nodules in immunodeficient mice within a certain time interval. Six-to-eight-week-old male NOD/SCID mice were randomly divided into groups (six mice/group) and maintained under standard conditions, according to institutional guidelines. Cells were suspended in a serum-free DMEM/Matrigel (BD Biosciences, USA) mixture (1:1 by volume), and injected subcutaneously into the flanks of recipient NOD/SCID mice. Tumor formation was monitored every two weeks following injection, and the size and incidence of tumors were recorded. The tumorigenicity experiment was terminated six weeks after injection, at which point mice with no apparent tumor nodules at the injection site were considered negative.

cDNA microarray
cDNA expression profiling was performed using total RNA with the GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, USA) according to the manufacturer’s instructions and a previous report [27].

Statistical analysis
Statistical analyses were performed using SPSS 20.0 software (IBM, Chicago, IL, USA). Experimental values for continuous variables were expressed as the mean ± standard error of the mean. The chi-squared test, Fisher’s exact probability tests, and the Student’s t-test were used as appropriate to evaluate the significance of differences in data between groups. If variances within groups were not homogeneous, a nonparametric Mann–Whitney test or a Wilcoxon signed-rank test was used. The relationships between sphere-formation capacity and TTR were analyzed using Kaplan–Meier survival curves and log-rank tests, respectively. A \( p \) value < 0.05 was considered statistically significant.
Results
HCC cell lines form spheres with CSC properties
Two HCC cell lines (Huh7 and Hep3B) were cultured in ultra-low attachment surface plates with serum-free medium, and both cell lines formed sphere clusters. As drug resistance is a main characteristic of CSCs, we treated sphere-forming cells with 5-FU, Sorafenib, or Doxorubicin to evaluate drug resistance. We found that the sphere-forming cells of both cell lines had greater tolerance to treatment with a high concentration of 5-FU (80 mmol/L), Sorafenib (5 μmol/L) and Doxorubicin (2 μmol/L) than their corresponding parental cells (Fig. 1a). These results suggest that these sphere-forming subgroup cells may have a survival advantage when exposed to cytotoxic drugs.

We also evaluated the colony-forming capabilities of HCC sphere cells, and found that the sphere cells proliferated significantly faster and formed bigger colonies than parental cells after three weeks of culture. We observed a greater number of colonies following seeding of 2000 cells in tumor sphere cell cultures compared with parental cells (Huh7 307.33 ± 29.00 vs. 148.33 ± 19.43, Hep3B 235.66 ± 14.85 vs. 97.67 ± 6.06; both p < 0.05) (Fig. 1b).

In vivo serial dilution tumorigenesis assays are considered to be the golden standard for evaluating CSC properties; therefore, parental and sphere Huh7 cells were transplanted in NOD/SCID mice. We found that as few as 500 Huh7 sphere cells were sufficient for tumor development, whereas, as many as 10^5 parental Huh7 cells were unable to initiate tumor in immunodeficient mice after four weeks. The same results were observed when 1000 cells were injected, resulting in a shorter tumor formation time (less than two weeks) (Fig. 1c, Table 1, Additional file 2: Table S2). These data confirm that HCC sphere cells have efficient tumor-initiating capacity.

The self-renewal potential of HCC sphere cells was also evaluated using three rounds of serial passaging (see Methods). Two days after adding 10% FBS, sphere cells attached onto plates and grew as adherent cells. We compared the expression of EPCAM, PROM-1 (CD133), ATP-binding cassette sub-family G member 2 (ABCG2), and THY1 (CD90) between the three sets of differentiated spheres by qRT-PCR. We found that expression of these genes was significantly higher when cells formed spheres. However, following addition of 10% FBS, spheres differentiated and the expression of these four stem cell markers decreased to the level of parental cells. Remarkably, these results were observed in three sequential generations (Fig. 1d). To further explore whether sphere formation rate increase over time, we observed the sphere formation rates in three sequential generations. Result showed significant increases of sphere formation number after every passage (Fig. 1e), indicating sphere formation percentage were escalating during serial passage. Furthermore, to confirm the qRT-PCR results, protein expression of EpCAM and CD133 in the third sphere generation and in differentiated sphere cells was evaluated with PE-conjugated anti-EpCAM/anti-CD133 antibodies (Fig. 1f).

Evaluation of sphere cells as CSCs in human HCC clinical specimens
To investigate the CSC traits of sphere cells derived from fresh clinical specimens, we first successfully generated 5 cases of primary HCC spheres from 9 patients. Typical images of primary HCC spheres were shown in Fig. 2a. We next evaluated the expression of CSC markers (EPCAM, PROM-1, THY1, CD24, ICAM1, KRT19, OCT4, NANOG, and SOX2) in these five paired samples (sphere and corresponding parental cells) by qRT-PCR and found that different marker expression patterns occurred in different primary tumor spheres (Fig. 2b). To further explore the CSC potential and tumorigenic capability of enriched sphere tumor cells, we injected primary sphere tumor cells and corresponding tumor cells from the one randomly selected patient into NOD/SCID mice. We observed a significant difference in tumor incidence between these two cell populations: as few as 200 primary sphere cells were sufficient for consistent tumor development in immunodeficient mice, while up to 10^6 parental tumor cells could not induce tumor formation (Table 2).

We further evaluated the correlation between tumor sphere formation and tumor malignancy. A total of 25 HCC patients including previous 9 patients were recruited, and 56% (14/25) of which formed tumor spheres. We found that tissues from patients with larger tumors (65.00% vs. 20.00%), multiple lesions (100.00% vs. 50.00%), satellite lesions (80.00% vs. 50.00%), or advanced tumor stage (60.00% vs. 40.00%), had more efficient sphere-forming capacity under serum-free conditions (Fig. 2d).

The role of the PPARα signaling pathway and SCD1 in maintaining stem characteristics of sphere cells
To identify the potential mechanism underlying the maintenance of stem-cell phenotypes of sphere-forming cells, a microarray analysis was performed to compare the different expression profiles between Huh7 sphere and parental cells. Using a foldchange of 2.0 as the cutoff, we identified 1844 up-regulated and 2386 down-regulated genes in sphere cells compared with parental cells; a cluster analysis demonstrated the discrete nature of these two cell types (Fig. 3a). Notably, several stem-cell markers including PROM-1 (CD133), KRT19, ABCG2, CD13, NEDD9, NANOG, SOX9, and ICAM1 were up-regulated in sphere cells, while mature
Fig. 1 (See legend on next page.)
hapatocyte markers, such as glucose-6-phosphatase (G6PC) and cytokeratin 8 (KRT8) were down-regulated in sphere cells (Fig. 3b). These findings were confirmed by qRT-PCR (Fig. 3c).

We performed further bioinformatic analyses, and found that the PPARα signaling pathway was the most significantly activated pathway according to KEGG pathway analysis. In addition, oxidation-reduction was the most significant biological process according to gene ontology analysis. Of note, SCD1 was the most up-regulated molecule involved in both the PPARα pathway and oxidation-reduction process, which suggested that SCD1 might be a key molecule involved in maintaining stem-cell phenotypes of sphere-forming tumor cells (Fig. 3d, e).

We further evaluated the expression of SCD1 and several other PPARα pathway-related genes. Compared with parental cells, the expression of key genes (SCD1, FABP1, PPARα, APOC3, PCK1, and SORBS1) involved in the PPARα pathway were significantly higher in sphere cells (Fig. 3f). Moreover, the expression of four genes (SCD1, FABP1, PPARα, and SORBS1) was significantly higher in primary sphere cells (Fig. 3g). Based on these data, we therefore speculated that the PPARα-SCD1 axis might play an important role in maintaining CSC properties of HCC sphere cells.

**Inhibition of the PPARα pathway or SCD1 induces loss of CSC properties**

To validate our speculation, a specific antagonist (GW6471) was used to inhibit the PPARα pathway to evaluate the role of PPARα and SCD1 in maintaining CSC properties [15]. We found that GW6471 treatment effectively decreased the sphere-forming capacity of parental Huh7 and Hep3B cells. Furthermore, treatment of parental HCC cells with a novel SCD1 inhibitor (PluriSIn #1) also decreased the sphere-forming capacity of Huh7 and Hep3B cells. To further confirm these results, we treated parental Huh7 and Hep3B cells with clofibric acid (CA), a PPARα pathway agonist, and PluriSIn #1. We found that CA could improve the sphere-formation capacity of HCC cells, while PluriSIn #1 could abolish the effect induced by PPARα activation. Moreover, qRT-PCR analysis confirmed that SCD1 served as a functional downstream factor of PPARα as its expression significantly decreased after GW6471 treatment (Fig. 4a).

We further treated primary spheres from 3 fresh specimens with CA, or PluriSIn #1, or combination of CA and PluriSIn #1. We found the results were similar to those of cell lines (Fig. 4b). Additionally, GW6471 or PluriSIn #1 treatment of HCC sphere cells not only resulted in the inhibition of sphere formation, but also could lead to gradual disintegration of spheres derived from HCC cells (Fig. 4c). Down-regulation of several stem-cell markers, including EPCAM, PROM-1 (CD133), KRT19, CD24, and ICAM1 was observed after GW6471 or PluriSIn #1 treatment in HCC cell lines (Fig. 4d). Taken together, these data implied the vital role of the PPARα-SCD1 axis in maintaining stem properties of HCC CSC cells, and demonstrate that inhibition of SCD1 might be a promising strategy to inhibit CSCs in HCC.

SCD1 plays a role in regulating Wnt/β-Catenin signaling, which is important for maintaining CSC properties. Using immunofluorescence staining, we observed that the expression pattern of β-Catenin in most Huh7 sphere cells was nuclear; however, after short-term (24 h) SCD1 inhibition, the expression pattern became membranous (Fig. 4e). To validate these findings, expression levels of four canonical

**Table 1 Comparison of Tumorigenic Capacity of Sphere-forming and Normal Cultured Huh7 Cells**

| Phenotypes            | No. of cells injected | 2 Weeks | 4 Weeks | 6 Weeks |
|-----------------------|----------------------|---------|---------|---------|
| Sphere-forming cells  | 5 × 10⁴               | 2/6     | 4/6     | 4/6     |
|                       | 1 × 10⁴               | 4/6     | 6/6     | 6/6     |
| Normal cultured cells | 1 × 10⁴               | 0/6     | 0/6     | 0/6     |
|                       | 1 × 10⁵               | 0/6     | 0/6     | 0/6     |
down-stream targets of β-Catenin (CCND1, FGF10, MYCN, and BMP4) were evaluated by qRT-PCR. As expected, we found that expression of all four targets was dramatically decreased after SCD1 inhibition, indicating that β-Catenin transcriptional activity was hindered by SCD1 inhibition (Fig. 4f). Collectively, our data suggest that SCD1 serves as a vital regulator of CSC maintenance in HCC via stabilization of β-Catenin transcriptional activity (Fig. 4g).

Discussion
The identification of tumorigenic liver CSCs could provide new insights into HCC pathogenesis and could have great therapeutic implications [7]. Although several populations of HCC cells have been identified as CSCs based on cell surface markers, the specificity of these markers is being challenged owing to the differential expression patterns of stem-cell markers in different cell lines or patient samples [28]. Due to the lack of a generally accepted biomarker for HCC CSCs, it is reasonable to identify CSC subpopulations on the basis of functional criteria [17, 29]. Our data show that sphere-forming assays are a useful tool for enriching HCC CSCs. Indeed, tumor sphere cells exhibited CSC properties, including proliferation, self-renewal, drug resistance, and

Table 2 Comparison of Tumorigenic Capacity of Primary Sphere Tumor cells and Primary CD45− Tumor cells

| Phenoatypes     | No. of cells injected | No. of Mice with Tumor Formation/Total No. of Mice with Cell Injection |
|-----------------|-----------------------|---------------------------------------------------------------------|
| Sphere cells    |                       | 2 Weeks  | 4 Weeks  | 6 Weeks  |
| 2 × 10⁴         | 0/6                   | 3/6      | 3/6      |
| 5 × 10⁵         | 0/6                   | 4/6      | 4/6      |
| 1 × 10⁶         | 1/6                   | 3/6      | 3/6      |
| 5 × 10⁷         | 2/6                   | 5/6      | 5/6      |
| CD45− cells     |                       | 2 Weeks  | 4 Weeks  | 6 Weeks  |
| 1 × 10⁵         | 0/6                   | 0/6      | 0/6      |
| 1 × 10⁶         | 0/6                   | 0/6      | 0/6      |
| 1 × 10⁷         | 0/6                   | 0/6      | 0/6      |

Fig. 2 CSC properties of sphere cells in fresh clinical HCC specimens and association between sphere formation and prognosis. a Representative photographs of spheres formed from 5 fresh clinical HCC specimens. Scale bar 50 μm. b Relative expression of CSC-related genes in 5 primary HCC spheres. The expression level of certain gene in sphere cells was normalized according to the expression of that in parental HCC cells. c Positive rates of sphere-formation in 25 patients stratified according to tumor size, number, satellite lesion, and tumor stage.
Fig. 3

(See legend on next page.)
high tumorigenicity. More importantly, contrary to the cell surface marker selection strategy, which only enriches one CSC subpopulation, our data show that sphere-forming culture enriches different subpopulations of CSCs with certain HCC biomarkers, indicating that this strategy could enrich the most complete CSC population from a bulk tumor. Therefore, this HCC CSC enrichment approach could provide a deep and comprehensive understanding of HCC tumorigenesis.

Sphere-forming culture is commonly used to retrospectively confirm a certain subpopulation of tumor cells with stem characteristics [11–15]. For HCC, only two studies have reported enrichment of stem-cell subpopulations through sphere-forming culture with HCC cell lines [26, 30]. In this study, we further validated the ability of sphere-forming culture to enrich the subpopulation with stem-cell properties from HCC cell lines, and, more importantly, the ability of this culture system to enrich CSCs from fresh primary tumors. To our knowledge, this is the first study to comprehensively identify sphere cells as CSCs in freshly resected tumor specimens. More importantly, we also observed that sphere-formation rates were positively correlated with advanced malignant phenotypes, implying that tumors with advanced malignant potential are more likely to contain higher numbers of CSCs population. Thus, sphere-forming culture might be a useful way to enrich HCC CSCs, and targeting these sphere cells might be an advantageous strategy to specifically eliminate CSCs with fewer side effects. Furthermore, screening for drug sensitivity in these cells might be a promising approach to select the most specific treatment regimen for HCC patients.

The underlying mechanisms of sustaining CSC properties in HCC sphere cells was investigated, and a novel PPARα-SCD1 axis was discovered. We found that maintenance of CSC properties was regulated by PPARα pathway activation, which up-regulated SCD1 expression and induced nuclear accumulation of β-Catenin. Additionally, inhibition of the PPARα pathway or SCD1 inhibition interfered with sphere formation, and decreased the expression of CSC-related markers, resulting in loss of CSC properties. Consistent with this, one recent study demonstrated that inhibition of PPARα could interfere with sphere formation and decrease SCD1 expression, indicating the requirement of this pathway in sphere formation and CSC maintenance [31].

Recently, accumulating evidence revealed that CSCs are characterized by a high plasticity in energy substrate metabolism, and increased lipid droplet accumulation is considered as the metabolism hallmark for CSCs. In HCC, previous studies found that HCC-derived CSCs could use lipid droplets as an internal energy reservoir to foster themselves growth under hypoxic environment via an epigenetic regulatory network [32, 33]. Our results stand well in line with these ideas that lipid metabolism played a vital role in regulating CSC traits in HCC and uncovered the significance of fatty acid. As the rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids from saturated fatty acids, SCD1 is overexpressed in several types of cancer [34–38]. Additionally, the livers of mouse or rats with SCD1 overexpression were susceptible to hepatocarcinogenesis [36], and SCD1 is also reported to be a biomarker for HCC aggressiveness [39, 40]. Our study indicates that the important role of SCD1 in HCC CSC maintenance occurs through regulation of the nuclear accumulation of β-Catenin, which is consistent with a recent study demonstrating that SCD1 was a vital promoter of the Wnt/β-Catenin signaling pathway [41]. Thus, targeting SCD1 could directly target the HCC stem cell subpopulation and may be a potential treatment strategy for HCC management in the future. Since LXR pathway was identified as a key metabolism regulator that rendered CSC traits for HCC cells, the crosstalk between SCD1 and LXR needs to be deeply investigated in the future.

There are some limitations of our study to be noted. First, the detailed mechanism underlying how PPARα regulates SCD1 expression remains elusive, and needs further exploration. Second, the correlation between SCD1 and other signaling pathways involved in regulating HCC stem cell phenotypes remains unknown. Additionally, although our data well demonstrated that sphere-forming cells exhibited impressive self-renew and differentiation potentials in vitro, in vivo serial passage assays are also needed in the future to systematically confirm the in vitro findings. These studies are ongoing in our laboratory.
Fig. 4 (See legend on next page.)
Conclusions
In summary, our data indicate that sphere-forming culture can effectively enrich the HCC CSC subpopulation, which is maintained by the PPARα-SCD1 axis. Moreover, we identified SCD1 as a key regulator of CSC properties in HCC sphere cells and suggest that targeting SCD1-related CSC machinery might provide a new insight in HCC treatment.

Additional files

Additional file 1: Table S1. Primers used in present study. (DOC 54 kb)
Additional file 2: Table S2. Volumes of tumors of the indicated groups when mouse were sacrificed. (DOCX 12 kb)

Abbreviations
S-FU: 5-Fluorouracil; ABCG2: ATP-binding cassette sub-family G member 2; APOC3: Apolipoprotein C3; BMP4: Bone morphogenetic protein 4; CCK-8: Cell Counting Kit-8; CCND1: Cyclin D1; CK19: Cytokeratin 19; CK8: Cytokeratin 8; CSC: Cancer stem cell; DIME: Dulbecco’s modified Eagle’s medium; EpcAM: Epithelial cell adhesion molecule; FABP1: Fatty acid binding protein 1; FBS: Fetal bovine serum; FGF10: Fibroblast growth factor 10; G6P: Glucose-6-phosphatase; HCC: Hepatocellular carcinoma; ICAM1: Intercellular adhesion molecule 1; NEDD9: Neural precursor cell expressed, developmentally down-regulated 9; N-myc: N-MYC proto-oncogene; OGT: Octamer binding protein 4; PCK1: Phosphoenolpyruvate carboxykinase 1; PE: Phycoerythrin; PPARα: Activation of the peroxisome proliferator-activated receptor-alpha; SCD1: Stearoyl-CoA desaturase; SORBS1: Sorbin and SH3 domain containing 1; SOX2: SRY-box 2

Acknowledgements
Not applicable.

Authors' contributions
Conception: XRY, XLM, YFS. Design of work: WG, XRY, XLM, and YFS; Acquisition, analysis, and interpretation of data: XLM, MNS, BH, ZJG, XZ, JWC, BLW, YZ, and YFS. Drafting the manuscript: XLM, BH, YC, and XRY. Critical revision of manuscript: JZ, BSP, WG, XRY, and JF; Final approval of manuscript: All authors.

Funding
Wei Guo was supported by the National Natural Science Foundation of China (81772626 and 81572064) and Key Developing Disciplines of Shanghai Municipal Commission of Health and Family Planning (2015SB0201). The funders had no role in the study design, data collection, data analysis, data interpretation and manuscript writing. Xin-Rong Yang was supported by the National Natural Science Foundation of China (81672839 and 81472676), National Key Research and Development Program of China (2016YFF0101405), the project from Shanghai Science and Technology Commission (14DZ1940302, 141119S2100), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12020103), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12020105). The funders had no role in the study design, data collection, data analysis, data interpretation and manuscript writing. Jia Fan was supported by the National High Technology Research and Development Program (863 Program) of China (2015AA020401), the State Key Program of National Natural Science of China (81330077), Specialized Research Fund for the Doctoral Program of Higher Education and Research Grants Council Earmarked Research Grants Joint Research Scheme (20130021140008), the Project from Shanghai Science and Technology Commission (14DZ1940300, 141119S2100), The Strategic Priority Research Program of the Chinese Academy of Science (XDA12020103). The funders had no role in the study design, data collection, data analysis, data interpretation and manuscript writing. Bei-Li Wang was supported by the Projects from Shanghai Science and Technology Commission (164119S2100). The funders had no role in the study design, data collection, data analysis, data interpretation and manuscript writing. Yun-Fan Sun was supported by National Natural Science Foundation of China (81602543) and the Sailing Program from the Shanghai and Technology Commission (1611F1401400). The funders had no role in the study design, data collection, data analysis, data interpretation and manuscript writing.

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Present study was performed in accordance with the 1975 Declaration of Helsinki. Approval for the use of human subjects was obtained from the research ethics committee of Zhongshan Hospital, and informed consent in written form was obtained from each individual enrolled in this study.

Consent for publication
Not applicable.

Competing interests
The authors declare that there are no conflicts of interest to disclose regarding funding from industrial sources or other disclosures with respect to this manuscript.

Author details
1Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, People’s Republic of China. 2Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, 136 Yi Xue Yuan Road, Shanghai 200032, People’s Republic of China. 3Cancer Research Institute, Xiangya School of Medicine, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha 410078, China.

(See figure on previous page.)
Fig. 4 PPARα-SCD1 axis maintained CSC properties of spheres via promoting nuclear accumulation of β-Catenin. a Number of spheres derived from 1000 HCC cells which were treated with GW6471, PluriSln #1, or combination of clofibric acid (CA) and PluriSln #1 (left), and Relative expression of SCD1 in sphere cells after PPARα inhibition. b Number of spheres derived from 1000 primary HCC cells which were treated with GW6471, PluriSln #1, or combination of CA and PluriSln #. c Left panel: Representative photographs of parental HCC cells treated with DMSO for 5 days as controls, or parental HCC cells treated with 25 μM GW6471 for 5 days, or sphere HCC cells treated with 25 μM GW6471 for 2 days. Right panel: Representative photographs of parental HCC cells treated with DMSO for 5 days as controls, or parental HCC cells treated with 20 μM PluriSln #1 for 5 days, or sphere HCC cells treated with 20 μM PluriSln #1 for 2 days. d Fold changes of CSC-related markers of HCC sphere cells after treated with GW6471 (upper) or PluriSln #1 (lower) for 2 days. Results were normalized according to the expression of control spheres cells. e Representative immunofluorescence images of a Huh7 sphere co-stained with anti-β-Catenin and DAPI without (upper panel) or with (lower panel) SCD1 inhibition. f Fold changes of target genes of β-Catenin of Huh7 (upper) and Hep3B (lower) after treatment with PluriSln #1 for 2 days. Results were normalized according to the expression of control spheres cells. g Simplified diagram of present study. *: P < 0.05; **: P < 0.001.
References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.
3. Bruix J, Gores GJ, Mazzaferrro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844–55.
4. Bruix J, Reg T, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–53.
5. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012;21:283–96.
6. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501:328–37.
7. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14:611–29.
8. Adorno-Cruz V, Kibria G, Liu X, et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res. 2015;75:924–32.
9. Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006;44:240–51.
10. Yang ZF, Ngai P, Ho DW, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008;47:919–28.
11. Haraguchi N, Ishii H, Minomori K, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010;120:3326–39.
12. Ma S, Tang KH, Chan YP, et al. miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 2010;6:94–707.
13. Yang ZF, Ngai P, Ho DW, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008;47:919–28.
14. Lee TK, Castillo A, Cheung VC, et al. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell. 2011;9:50–63.
15. Yang W, Wang C, Liu Y, et al. OX46(+) tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J Hepatol. 2012;57:613–20.
16. Liu S, Lin N, Yu X, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology. 2013;144:1031–41.
17. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011;8:486–98.
18. Zhang Y, Xu W, Guo H, et al. NOTCH1 signaling regulates self-renewal and platinum chemoresistance of cancer stem-like cells in human non-small cell lung cancer. Cancer Res. 2017;77:1082–91.
19. Pointer KB, Clark PA, Elecirei KW, et al. Administration of non-Torsadogenic human ether-a-go-go-related gene inhibitors is associated with better survival for high hERG-expressing glioblastoma patients. Clin Cancer Res. 2017;23:73–80.
20. Ioris RM, Galie M, Ramadori G, et al. SIRT6 suppresses cancer stem-like capacity in tumors with PIK3 activation independently of its deacetylase activity. Cell Rep. 2017;18:1858–68.
21. Liu C, Liu R, Zhang D, et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat Commun. 2017. https://doi.org/10.1038/ncomms14270.
22. Wang J, Zhang B, Wu H, et al. CD51 correlates with the TGF-beta pathway and is a functional marker for colorectal cancer stem cells. Oncogene. 2013;32:1351–63.
23. Keyser SB, Le PN, Miller B, et al. Regulation of head and neck squamous carcinoma stem cells by PI3K and SOX2. J Natl Cancer Inst. 2016;108(1). https://doi.org/10.1093/jnci/djw189.
24. Nakao M, Nakao M, Nakao M, et al. Three-dimensional Organotypic culture models of human hepatocellular carcinoma. Sci Rep. 2016;6:21174.
25. Liu Z, Dai X, Wang T, et al. Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells. Cancer Lett. 2017. https://doi.org/10.1016/j.canlet.2017.04017.
26. Chen Y, Yu D, Zhang H, et al. CD133(+) EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma HuH7 cells. Int J Biol Sci. 2012;8:992–1004.
27. Okuma HS, Koizumi F, Hirakawa A, et al. Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies. Br J Cancer. 2016;115:411–9.
28. Chen J, Jin R, Zhao J, et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 2015;367:11–11.
29. Shen Y, Jia D, Wang XL, et al. Heterogeneity of hepatocellular carcinoma contributes to cancer progression. Curr Rev Oncol Hematol. 2015;9:347–57.
30. Kwon T, Bae K, Park YH, et al. Peroxiredoxin II is essential for maintaining Steinness by redox regulation in liver cancer cells. Stem Cells. 2016;34:1188–97.
31. Tanaka N, Moriya K, Kiyosawa K, et al. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest. 2008;118:683–94.
32. Lo Re O, Douet J, Buschbeck M, et al. Histone variant marcoH2A1 renews carbohydrate and lipid metabolism of hepatocellular carcinoma cells towards cancer stem cells. Epigenetics. 2018;13:829–45.
33. Lo Re O, Fusilli C, Rappa F, et al. Induction of cancer stem cell stemlessness by depletion of marcohistone H2A1 in hepatocellular carcinoma. Hepatology. 2018;67:636–50.
34. Nota A, De Vitis C, Pisanu ME, et al. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. Oncogene. 2017;36:4573–84.
35. EI HR, Pinna G, Cabaud O, et al. miR-600 acts as a bimodal switch that regulates breast cancer stem cell fate through WNT signaling. Cell Rep. 2017;18:2256–68.
36. Igal RA, Stearoyl-CoA desaturase-1: new insights into a central regulator of cancer metabolism. Biochim Biophys Acta. 2016;1861:1865–80.
37. Li J, Condello S, Thomas-Pepin J, et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell. 2017;20:303–14.
38. Angelucci C, Maulucci G, Colabianchi A, et al. Stearoyl-CoA desaturase 1 and paracrine diffusible signals have a major role in the promotion of breast cancer cell migration induced by cancer-associated fibroblasts. Br J Cancer. 2015;112:1675–86.
39. Budhu A, Roesler S, Zhao X, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology. 2013;144:1066–75.
40. Huang GM, Jiang QH, Cai C, et al. SCD1 negatively regulates autophagy -induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway. Cancer Lett. 2015;358:180–90.
41. Lai K, Kweon SM, Chi F, et al. Stearoyl-CoA desaturase promotes liver fibrosis and tumor development in mice via a Wnt positive-signaling loop by stabilization of low-density lipoprotein-receptor-related proteins 5 and 6. Gastroenterology. 2017;152:1477–91.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.